Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ADC Therapy in HR+/HER2- Advanced Breast Cancer
NCT07162259Phase 4Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer (2 cohorts). Primary endpoint: Progression-Free Survival 1 at 24 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecansacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07162259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162259.